Blog: RESPIRERX PHARMACEUTICALS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) – Marketscreener.com

Item 7.01. Regulation FD Disclosure.

ResolutionRx, the pharmaceutical cannabinoid business unit of RespireRx
Pharmaceuticals Inc. (the “Company”), participated in the 5th International
Cannabinoid-Derived Pharmaceuticals Summit, which took place September 7-8, 2022
in Boston, MA. As an invited guest speaker, Arnold S. Lippa, Ph.D., the
Company’s Interim President, Interim Chief Executive Officer, and Chief
Scientific Officer presented a talk (“Presentation Materials”) entitled “Drug
Re-purposing: A Case Study of Dronabinol”, in which he described the advantages
of re-purposing an already FDA approved drug for a new therapeutic indication,
using our development program for dronabinol as an example. Dr. Lippa reviewed
the clinical and operational programs completed to date and then focused on our
new lipid-based nanotechnology formulation for dronabinol that is intended to
create a superior approach to administering oral dronabinol as well as extend
and solidify our intellectual property base. During the summit, he also
participated in meetings with third parties.

The information in this Item 7.01 and the document attached as Exhibit 99.1 is
being furnished and shall not be deemed “filed” for purposes of Section 18 of
the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor
otherwise subject to the liabilities of that section, nor incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits.



Exhibit Number   Exhibit Description
99.1               RespireRx-ResolutionRx Slide Presentation
104              Cover Page Interactive Data File (embedded within the Inline XBRL
                 document)










Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: September 13, 2022 RESPIRERX PHARMACEUTICALS INC.

                         (Registrant)

                         By: /s/ Jeff E. Margolis
                             Jeff E. Margolis
                             SVP, CFO, Secretary and Treasurer

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s